HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CD5 negative B-cell chronic lymphocytic leukemia: clinical and biological features of 42 cases.

Abstract
Chronic lymphocytic leukemia cell (CLL) usually (95%) express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells. However, among B CLL, 7 to 20% do not express CD5. The significance of the lack of CD5 expression remains unclear. We reviewed 42 consecutive CD5- B CLL seen in three French medical centers from 1985 to 1991 and compared them with 79 CD5+ B CLL. Immunophenotype studies were performed using indirect immunofluorescence under light microscopy as well as flow cytometry after 1988. B CLL was considered to be CD5 negative when less than 5% of mononuclear cells expressed CD5 after subtraction of the number of T-cells. Cases with CD5- B CLL had isolated splenomegaly more frequently (p = 2.10(-7)). They frequently expressed a higher level of surface immunoglobulin (S-Ig) or the switch mu/delta phenotype (p = 4.7 10(-2)). The median survival time was not reached but no significant difference between CD5 negative and positive B CLL was observed at the time of our data analysis (p = 0.97). Clinical presentation of CD5- B CLL seems to be different from other forms of B CLL. Although, no conclusion can be reached in terms of prognosis, CLL with low expression of CD5 should be regarded as a subtype of CLL with a different clinical presentation than CD5+ CLL.
AuthorsG Cartron, C Linassier, J L Bremond, B Desablens, M T Georget, B Fimbel, F Luthier, J L Dutel, J P Lamagnere, P Colombat
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 31 Issue 1-2 Pg. 209-16 (Sep 1998) ISSN: 1042-8194 [Print] United States
PMID9720730 (Publication Type: Journal Article)
Chemical References
  • CD5 Antigens
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • CD5 Antigens (blood)
  • Female
  • France (epidemiology)
  • Humans
  • Immunophenotyping
  • Incidence
  • Leukemia, Lymphocytic, Chronic, B-Cell (epidemiology, immunology, mortality)
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: